56 related articles for article (PubMed ID: 8353071)
1. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
Bergmann L; Fenchel K; Jahn B; Mitrou PS; Hoelzer D
Ann Oncol; 1993 May; 4(5):371-5. PubMed ID: 8353071
[TBL] [Abstract][Full Text] [Related]
2. Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.
Palermo G; Maisel D; Barrett M; Smith H; Duchateau-Nguyen G; Nguyen T; Yeh RF; Dufour A; Robak T; Dornan D; Weisser M;
Blood Cancer J; 2015 Oct; 5(10):e353. PubMed ID: 26430724
[TBL] [Abstract][Full Text] [Related]
3. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.
Kay NE; Shanafelt TD; Call TG; Wu W; Laplant BR
Leuk Lymphoma; 2009 Apr; 50(4):588-92. PubMed ID: 19373657
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of theophylline in chronic lymphocytic leukemia.
Makower D; Malik U; Novik Y; Wiernik PH
Med Oncol; 1999 Apr; 16(1):69-71. PubMed ID: 10382946
[TBL] [Abstract][Full Text] [Related]
5. The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
Fatima N; Best OG; Belov L; Christopherson RI
Leuk Lymphoma; 2024 Feb; 65(2):242-249. PubMed ID: 37933638
[TBL] [Abstract][Full Text] [Related]
6. Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab.
Bacova B; Kohutova Z; Zubata I; Gaherova L; Kucera P; Heizer T; Mikesova M; Karel T; Novak J
Clin Exp Med; 2023 Jun; 23(2):371-379. PubMed ID: 35352210
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of innate immune response ameliorates Zika virus-induced neurogenesis deficit in human neural stem cells.
Xu P; Gao J; Shan C; Dunn TJ; Xie X; Xia H; Zou J; Thames BH; Sajja A; Yu Y; Freiberg AN; Vasilakis N; Shi PY; Weaver SC; Wu P
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009183. PubMed ID: 33657175
[TBL] [Abstract][Full Text] [Related]
8. Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?
Park J; Lim SH; Kim SH; Yun J; Kim CK; Lee SC; Won JH; Hong DS; Park SK
Korean J Intern Med; 2020 Jul; 35(4):957-969. PubMed ID: 32306712
[TBL] [Abstract][Full Text] [Related]
9. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens.
Yamasaki S; Miyagi-Maeshima A; Kakugawa Y; Matsuno Y; Ohara-Waki F; Fuji S; Morita-Hoshi Y; Mori M; Kim SW; Mori S; Fukuda T; Tanosaki R; Shimoda T; Tobinai K; Saito D; Takaue Y; Teshima T; Heike Y
Int J Hematol; 2013 Mar; 97(3):421-6. PubMed ID: 23435651
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus oesophagitis following treatment with fludarabine for refractory lymphoplasmacytic lymphoma.
Pyatt N; Mitra S
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22771414
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine in the treatment of chronic lymphocytic leukemia: a review.
Ricci F; Tedeschi A; Morra E; Montillo M
Ther Clin Risk Manag; 2009 Feb; 5(1):187-207. PubMed ID: 19436622
[TBL] [Abstract][Full Text] [Related]
13. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.
Robak T
Drugs Aging; 2005; 22(12):983-1012. PubMed ID: 16363884
[TBL] [Abstract][Full Text] [Related]
14. Immune defects in patients with chronic lymphocytic leukemia.
Ravandi F; O'Brien S
Cancer Immunol Immunother; 2006 Feb; 55(2):197-209. PubMed ID: 16025268
[TBL] [Abstract][Full Text] [Related]
15. Current and developing chemotherapy for CLL.
Montserrat E
Med Oncol; 2002; 19 Suppl():S11-9. PubMed ID: 12180487
[TBL] [Abstract][Full Text] [Related]
16. Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.
Wijermans PW; van Groningen K; van Royen EA; Bruijn JA
Ann Hematol; 1994 Jun; 68(6):307-10. PubMed ID: 8038237
[TBL] [Abstract][Full Text] [Related]
17. Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
Montalban C; Liaño F; Aguilera A
Postgrad Med J; 1994 Sep; 70(827):651-2. PubMed ID: 7971632
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine in the management of malignant lymphomas.
Hiddemann W; Pott-Hoeck C
Drugs; 1994; 47 Suppl 6():50-6. PubMed ID: 7525189
[TBL] [Abstract][Full Text] [Related]
19. Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.
Juliusson G
Drugs; 1994; 47 Suppl 6():19-29. PubMed ID: 7525186
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
